Vanguard Group Inc. Increases Stock Position in Alphatec Holdings, Inc. $ATEC

Vanguard Group Inc. grew its position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) by 2.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,815,058 shares of the medical technology company’s stock after purchasing an additional 158,295 shares during the quarter. Vanguard Group Inc. owned approximately 4.59% of Alphatec worth $99,091,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Alphatec by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,005 shares of the medical technology company’s stock valued at $750,000 after purchasing an additional 3,196 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Alphatec in the first quarter valued at approximately $257,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Alphatec by 18.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 265,907 shares of the medical technology company’s stock worth $2,696,000 after acquiring an additional 41,264 shares during the last quarter. AlphaQuest LLC increased its holdings in shares of Alphatec by 37.8% in the 2nd quarter. AlphaQuest LLC now owns 12,012 shares of the medical technology company’s stock valued at $133,000 after acquiring an additional 3,297 shares during the period. Finally, Nisa Investment Advisors LLC raised its position in Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after purchasing an additional 1,045 shares during the last quarter. 66.35% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP David Sponsel sold 60,425 shares of the company’s stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $13.79, for a total value of $833,260.75. Following the sale, the executive vice president owned 349,500 shares in the company, valued at $4,819,605. This represents a 14.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director David R. Pelizzon sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $19.66, for a total value of $4,915,000.00. Following the completion of the transaction, the director directly owned 10,395,045 shares of the company’s stock, valued at $204,366,584.70. The trade was a 2.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,336,125 shares of company stock valued at $27,174,878 in the last quarter. Insiders own 20.90% of the company’s stock.

Wall Street Analyst Weigh In

ATEC has been the topic of a number of recent research reports. Lake Street Capital restated a “buy” rating on shares of Alphatec in a research note on Wednesday, February 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Alphatec in a research report on Monday, December 29th. Wall Street Zen raised Alphatec from a “hold” rating to a “buy” rating in a research note on Saturday, January 31st. Piper Sandler reiterated an “overweight” rating on shares of Alphatec in a research note on Wednesday, February 25th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price target on shares of Alphatec in a research note on Monday, January 12th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Alphatec presently has an average rating of “Moderate Buy” and a consensus price target of $22.82.

Alphatec Trading Down 0.2%

Shares of ATEC stock opened at $13.00 on Thursday. The business’s fifty day moving average price is $16.28 and its 200 day moving average price is $17.05. The firm has a market capitalization of $1.97 billion, a PE ratio of -13.68 and a beta of 1.02. The company has a debt-to-equity ratio of 40.35, a current ratio of 2.06 and a quick ratio of 1.28. Alphatec Holdings, Inc. has a 1-year low of $8.81 and a 1-year high of $23.29.

Alphatec (NASDAQ:ATEC) last released its earnings results on Tuesday, February 24th. The medical technology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $212.93 million during the quarter, compared to analyst estimates of $212.67 million. During the same period last year, the business posted ($0.23) EPS. Alphatec’s revenue was up 20.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Alphatec Profile

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.